Affiliation:
1. Muğla Sıtkı Koçman University
2. Bilecik Seyh Edebali University
3. Istanbul University
Abstract
Abstract
In this study, we developed a process to identify an HIV-1 protein target and a new drug candidate. Genomic analysis was conducted on HIV-1 genomes to identify a viable target for disrupting viral replication and the reverse transcriptase enzyme. Based on MAUVE analysis, we selected the RNase H activity of the reverse transcriptase as the potential target due to its low mutation rate and high conservation. We screened 94,000 small molecule inhibitors and performed virtual screening. Molecular dynamics simulations and MM/PBSA were used to validate hit compounds' stability and binding free energy. Phomoarcherin B, known for its anticancer properties, emerged as the top candidate, showing potential as an inhibitor of HIV-1 reverse transcriptase RNase H activity.
Publisher
Research Square Platform LLC
Reference62 articles.
1. Hemelaar J (2012) "The origin and diversity of the HIV-1 pandemic," (in eng), Trends Mol Med, vol. 18, no. 3, pp. 182 – 92, Mar doi: 10.1016/j.molmed.2011.12.001
2. WHO. "HIV data and statistics." https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics (accessed 2023)
3. UNAIDS, "Global HIV & AIDS statistics " https://www.unaids.org/en/resources/fact-sheet (accessed 2023).
4. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic," (in eng);Cohen MS;J Clin Invest
5. Kirchhoff F (2013) "HIV Life Cycle: Overview" pp. 1–9